Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- BofA lifts targets on AMD and ARM, raises CPU TAM to $170bn
Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey
August 7, 2018 3:32 PM EDTSunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.
Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More
Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen
August 7, 2018 3:31 PM EDTCowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More
Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection
August 7, 2018 9:34 AM EDTCantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.
Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More
BioMarin Pharma (BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (ONCE)
August 7, 2018 8:20 AM EDTBioMarin Pharma (NASDAQ: BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (NASDAQ: ONCE)
Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07
August 7, 2018 7:35 AM EDT(Updated)
Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($2.07), $1.97 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $29 million.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A... More
